
Europe - DUB:UPR - IE00BJ5FQX74 - Common Stock
The current stock price of UPR.I is 3.84 EUR. In the past month the price decreased by -0.13%. In the past year, price increased by 69.91%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABG.DE | CENCORA INC | 22.67 | 59.24B | ||
| AMP.MI | AMPLIFON SPA | 24.55 | 3.22B | ||
| FAGR.BR | FAGRON | 17.42 | 1.51B | ||
| ILM1.DE | MEDIOS AG | 16.59 | 313.26M | ||
| BLC.PA | BASTIDE LE CONFORT MEDICAL | 343.57 | 177.25M | ||
| VMED.DE | VIROMED MEDICAL AG | N/A | 72.90M |
Uniphar Plc engages in the provision of services within the pharmaceutical and healthcare sector. The firm is focused on improving access to pharmaco-medical products and therapies. The company operates through three divisions: Uniphar Medtech, Uniphar Pharma, and Uniphar Supply Chain & Retail. Its Uniphar Medtech division provides outsourced services, specifically sales, distribution, and support services to medical device manufacturers. Uniphar Pharma division operates a global business with valued services across the lifecycle of a pharmaceutical product. This division operates through on demand and pharma services business units. Uniphar Supply Chain & Retail division provides both pre-wholesale and wholesale distribution of pharmaceutical, healthcare, and animal health products to pharmacies, hospitals, and veterinary surgeons in Ireland. The company operates a network of pharmacies under the Life, Allcare, Hickey’s and McCauleys brands. The company also provides services and support that help independent community pharmacies.
UNIPHAR PLC
4045 Kingswood Road, Citywest Business Park
DUBLIN DUBLIN IE
Employees: 3500
Phone: 35314687501
Uniphar Plc engages in the provision of services within the pharmaceutical and healthcare sector. The firm is focused on improving access to pharmaco-medical products and therapies. The company operates through three divisions: Uniphar Medtech, Uniphar Pharma, and Uniphar Supply Chain & Retail. Its Uniphar Medtech division provides outsourced services, specifically sales, distribution, and support services to medical device manufacturers. Uniphar Pharma division operates a global business with valued services across the lifecycle of a pharmaceutical product. This division operates through on demand and pharma services business units. Uniphar Supply Chain & Retail division provides both pre-wholesale and wholesale distribution of pharmaceutical, healthcare, and animal health products to pharmacies, hospitals, and veterinary surgeons in Ireland. The company operates a network of pharmacies under the Life, Allcare, Hickey’s and McCauleys brands. The company also provides services and support that help independent community pharmacies.
The current stock price of UPR.I is 3.84 EUR. The price decreased by -2.78% in the last trading session.
UNIPHAR PLC (UPR.I) has a dividend yield of 0.87%. The yearly dividend amount is currently 0.02.
UPR.I has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
UPR.I stock is listed on the Euronext Dublin exchange.
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on UPR.I.
You can find the ownership structure of UNIPHAR PLC (UPR.I) on the Ownership tab.
ChartMill assigns a technical rating of 6 / 10 to UPR.I. When comparing the yearly performance of all stocks, UPR.I is one of the better performing stocks in the market, outperforming 87.47% of all stocks.
ChartMill assigns a fundamental rating of 5 / 10 to UPR.I. While UPR.I belongs to the best of the industry regarding profitability, there are concerns on its financial health.
Over the last trailing twelve months UPR.I reported a non-GAAP Earnings per Share(EPS) of 0.22. The EPS increased by 16.84% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 2.3% | ||
| ROA | 4.25% | ||
| ROE | 17.78% | ||
| Debt/Equity | 1.21 |
12 analysts have analysed UPR.I and the average price target is 4.93 EUR. This implies a price increase of 28.41% is expected in the next year compared to the current price of 3.84.
For the next year, analysts expect an EPS growth of 13.37% and a revenue growth 7.78% for UPR.I